ZTS VS REGN Stock Comparison
Performance
ZTS100/100
100/100
ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.
REGN23/100
23/100
REGN returned 10.99% in the last 12 months. Based on SPY's performance of 15.09%, its performance is below average giving it a score of 22 of 100.
Analyst Price Targets
ZTS75/100
75/100
21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.
REGN68/100
68/100
26 analysts offer 12-month price targets for REGN. Together, they have an average target of 791.45, the most optimistic target put REGN at 976 within 12-months and the most pessimistic has REGN at 604.
Technicals
ZTS82/100
82/100
ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.
REGN86/100
86/100
REGN receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.
Earnings
ZTS53/100
53/100
ZTS has missed earnings 2 times in the last 20 quarters.
REGN100/100
100/100
REGN has missed earnings 1 times in the last 20 quarters.
Profit
ZTS78/100
78/100
Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.
REGN80/100
80/100
Out of the last 20 quarters, REGN has had 20 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
ZTS50/100
50/100
ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
REGN57/100
57/100
REGN has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.
Dividend
ZTS35/100
35/100
ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.
REGN
"Dividend" not found for REGN
Sentiment
ZTS
"Sentiment" not found for ZTS
REGN72/100
72/100
REGN had a bullish sentiment score of 72.04% across Twitter and StockTwits over the last 12 months. It had an average of 38.16 posts, 65.65 comments, and 370.30 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
ZOETIS INC. Summary
New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Regeneron Pharmaceuticals Inc Summary
Nasdaq / REGN
Healthcare
Biotechnology
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ZTS to other companies in the same or a similar industry.